Literature DB >> 22427535

Apolipoprotein A-I attenuates ovalbumin-induced neutrophilic airway inflammation via a granulocyte colony-stimulating factor-dependent mechanism.

Cuilian Dai1, Xianglan Yao, Karen J Keeran, Gayle J Zywicke, Xuan Qu, Zu-Xi Yu, Pradeep K Dagur, J Philip McCoy, Alan T Remaley, Stewart J Levine.   

Abstract

Apolipoprotein A-I (apoA-I) is a key component of high-density lipoproteins that mediates reverse cholesterol transport from cells and reduces vascular inflammation. We investigated whether endogenous apoA-I modulates ovalbumin (OVA)-induced airway inflammation in mice. We found that apoA-I expression was significantly reduced in the lungs of OVA-challenged, compared with saline-challenged, wild-type (WT) mice. Next, to investigate the role of endogenous apoA-I in the pathogenesis of OVA-induced airway inflammation, WT and apoA-I(-/-) mice were sensitized by intraperitoneal injections of OVA and aluminum hydroxide, followed by multiple nasal OVA challenges for 4 weeks. OVA-challenged apoA-I(-/-) mice exhibited a phenotype of increased airway neutrophils compared with WT mice, which could be rescued by an administration of a 5A apoA-I mimetic peptide. Multiple pathways promoted neutrophilic inflammation in OVA-challenged apoA-I(-/-) mice, including the up-regulated expression of (1) proinflammatory cytokines (IL-17A and TNF-α), (2) CXC chemokines (CXCL5), (3) vascular adhesion molecules (i.e., vascular cell adhesion molecule-1), and (4) granulocyte colony-stimulating factors (G-CSF). Because concentrations of G-CSF in bronchoalveolar lavage fluid (BALF) were markedly increased in OVA-challenged apoA-I(-/-) mice, we hypothesized that enhanced G-CSF expression may represent the predominant pathway mediating increased neutrophilic inflammation. This was confirmed by the intranasal administration of a neutralizing anti-G-CSF antibody, which significantly reduced BALF neutrophilia by 72% in OVA-challenged apoA-I(-/-) mice, compared with mice that received a control antibody. We conclude that endogenous apoA-I negatively regulates OVA-induced neutrophilic airway inflammation, primarily via a G-CSF-dependent mechanism. Furthermore, these findings suggest that apoA-I may play an important role in modulating the severity of neutrophilic airway inflammation in asthma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22427535      PMCID: PMC3423466          DOI: 10.1165/rcmb.2011-0322OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  51 in total

1.  Human neutrophil integrin alpha9beta1: up-regulation by cell activation and synergy with beta2 integrins during adhesion to endothelium under flow.

Authors:  Agnès Mambole; Sylvain Bigot; Dominique Baruch; Philippe Lesavre; Lise Halbwachs-Mecarelli
Journal:  J Leukoc Biol       Date:  2010-04-30       Impact factor: 4.962

Review 2.  Neutrophils, from marrow to microbes.

Authors:  Niels Borregaard
Journal:  Immunity       Date:  2010-11-24       Impact factor: 31.745

Review 3.  Asthma.

Authors:  Christopher H Fanta
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

Review 4.  Importance of cytokines in murine allergic airway disease and human asthma.

Authors:  Fred D Finkelman; Simon P Hogan; Gurjit K Khurana Hershey; Marc E Rothenberg; Marsha Wills-Karp
Journal:  J Immunol       Date:  2010-02-15       Impact factor: 5.422

5.  Apolipoprotein E negatively regulates house dust mite-induced asthma via a low-density lipoprotein receptor-mediated pathway.

Authors:  Xianglan Yao; Karin Fredriksson; Zu-Xi Yu; Xiuli Xu; Nalini Raghavachari; Karen J Keeran; Gayle J Zywicke; Minjung Kwak; Marcelo J A Amar; Alan T Remaley; Stewart J Levine
Journal:  Am J Respir Crit Care Med       Date:  2010-07-09       Impact factor: 21.405

Review 6.  The many paths to asthma: phenotype shaped by innate and adaptive immunity.

Authors:  Hye Young Kim; Rosemarie H DeKruyff; Dale T Umetsu
Journal:  Nat Immunol       Date:  2010-06-18       Impact factor: 25.606

7.  5A, an apolipoprotein A-I mimetic peptide, attenuates the induction of house dust mite-induced asthma.

Authors:  Xianglan Yao; Cuilian Dai; Karin Fredriksson; Pradeep K Dagur; J Philip McCoy; Xuan Qu; Zu-Xi Yu; Karen J Keeran; Gayle J Zywicke; Marcelo J A Amar; Alan T Remaley; Stewart J Levine
Journal:  J Immunol       Date:  2010-11-29       Impact factor: 5.422

8.  Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.

Authors:  Tae Hoon Kim; Yoo Hoon Lee; Kyung Hun Kim; Shin Hwa Lee; Ji Yeon Cha; Eun Kyoung Shin; Seok Jung; An Soo Jang; Sung Woo Park; Soo Taek Uh; Young Hoon Kim; Jai Soung Park; Hwa Gyoun Sin; Wook Youm; Eun Suk Koh; Sun Young Cho; Young Ki Paik; Tai Youn Rhim; Choon Sik Park
Journal:  Am J Respir Crit Care Med       Date:  2010-05-12       Impact factor: 21.405

9.  Requisite role of the cholinergic alpha7 nicotinic acetylcholine receptor pathway in suppressing Gram-negative sepsis-induced acute lung inflammatory injury.

Authors:  Xiao Su; Michael A Matthay; Asrar B Malik
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

Review 10.  Eosinophilic and neutrophilic inflammation in asthma: insights from clinical studies.

Authors:  John V Fahy
Journal:  Proc Am Thorac Soc       Date:  2009-05-01
View more
  22 in total

1.  A novel apolipoprotein C-II mimetic peptide that activates lipoprotein lipase and decreases serum triglycerides in apolipoprotein E-knockout mice.

Authors:  Marcelo J A Amar; Toshihiro Sakurai; Akiko Sakurai-Ikuta; Denis Sviridov; Lita Freeman; Lusana Ahsan; Alan T Remaley
Journal:  J Pharmacol Exp Ther       Date:  2014-11-13       Impact factor: 4.030

2.  Revisiting "Good" and "Bad" Cholesterol. The Battle over Flow through Arteries Now Shifts to Flow through Airways.

Authors:  Michael B Fessler
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

Review 3.  The A's Have It: Developing Apolipoprotein A-I Mimetic Peptides Into a Novel Treatment for Asthma.

Authors:  Xianglan Yao; Elizabeth M Gordon; Amisha V Barochia; Alan T Remaley; Stewart J Levine
Journal:  Chest       Date:  2016-06-18       Impact factor: 9.410

Review 4.  A New Frontier in Immunometabolism. Cholesterol in Lung Health and Disease.

Authors:  Michael B Fessler
Journal:  Ann Am Thorac Soc       Date:  2017-11

Review 5.  Regulation of Adaptive Immunity in Health and Disease by Cholesterol Metabolism.

Authors:  Michael B Fessler
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

6.  Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma.

Authors:  Amisha V Barochia; Maryann Kaler; Rosemarie A Cuento; Elizabeth M Gordon; Nargues A Weir; Maureen Sampson; Joseph R Fontana; Sandra MacDonald; Joel Moss; Vincent Manganiello; Alan T Remaley; Stewart J Levine
Journal:  Am J Respir Crit Care Med       Date:  2015-05-01       Impact factor: 21.405

7.  Treatment options in type-2 low asthma.

Authors:  Timothy S C Hinks; Stewart J Levine; Guy G Brusselle
Journal:  Eur Respir J       Date:  2021-01-21       Impact factor: 16.671

8.  ATP-binding cassette transporter 1 attenuates ovalbumin-induced neutrophilic airway inflammation.

Authors:  Cuilian Dai; Xianglan Yao; Boris Vaisman; Todd Brenner; Katharine S Meyer; Meixia Gao; Karen J Keeran; Gayle Z Nugent; Xuan Qu; Zu-Xi Yu; Pradeep K Dagur; J Philip McCoy; Alan T Remaley; Stewart J Levine
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

9.  Antagonism of scavenger receptor CD36 by 5A peptide prevents chronic kidney disease progression in mice independent of blood pressure regulation.

Authors:  Ana Carolina P Souza; Alexander V Bocharov; Irina N Baranova; Tatyana G Vishnyakova; Yuning G Huang; Kenneth J Wilkins; Xuzhen Hu; Jonathan M Street; Alejandro Alvarez-Prats; Adam E Mullick; Amy P Patterson; Alan T Remaley; Thomas L Eggerman; Peter S T Yuen; Robert A Star
Journal:  Kidney Int       Date:  2016-04       Impact factor: 10.612

10.  The 5A apolipoprotein A-I (apoA-I) mimetic peptide ameliorates experimental colitis by regulating monocyte infiltration.

Authors:  Tobias M Nowacki; Alan T Remaley; Dominik Bettenworth; Michel Eisenblätter; Thorsten Vowinkel; Felix Becker; Thomas Vogl; Johannes Roth; Uwe J Tietge; Andreas Lügering; Jan Heidemann; Jerzy-Roch Nofer
Journal:  Br J Pharmacol       Date:  2016-08-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.